BERKELEY, Calif. and OSS, Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq: ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that Wiebe Olijve, PhD, a member of its scientific advisory board and co-founder of Aduro Biotech Europe (formerly known as BioNovion), has been named a Knight in the Order of the Netherlands Lion. This prestigious award was bestowed on Dr Olijve by His Majesty King Willem-Alexander of the Netherlands for his outstanding international contribution to the development of innovative and life-saving medicines. Dr Olijve received the Royal Decoration from the Mayor of Oss during the Aduro Biotech Europe Partners in Immuno-Oncology symposium on November 20.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c6babad7-a3f7-4dd3-a456-8cb67821fd1b
“Dr Olijve’s achievements have dramatically improved the health of countless people in The Netherlands and globally. His pioneering work in biotechnology was key to creating new classes of drugs and vaccines based on recombinant DNA technology. More recently, as a co-founder of BioNovion, he was a key contributor to the development of innovative antibodies with potential for treating cancer, including Aduro’s anti-APRIL program, which is expected to enter clinical studies in 2017,” said Hans van Eenennaam, PhD, chief operational officer of Aduro Biotech Europe. “We extend our heartfelt congratulations to Wiebe and are honoured to have him as a member of our scientific advisory board.”
“On behalf of the city of Oss, I would like to congratulate Wiebe Olijve with this Decoration, which recognises his great achievements in drug discovery and development. Not only have his achievements made a significant impact on the health of so many people, but the development and manufacturing of products, such as Puregon and Keytruda, in the Oss area have been and still are an important source of employment for the city,” said Mayor Wobine Buijs-Glaudemans.
Achievement in Dr Olijve’s distinguished career include:
- First person to apply recombinant DNA technology in Netherlands-based pharmaceutical labs, resulting in the production of the world’s first recombinant DNA-based vaccine (1981).
- Inventor of recombinant follicle-stimulating hormone (Puregon® (follicle stimulating hormone), which has served the medical need of many couples who suffer from infertility. Over one million babies have been born with the help of Puregon.
- Founder of Organon Research Center USA, site of ground breaking research that lead to the discovery of Keytruda® (pembrolizumab).
- Co-founder of BioNovion, a company acquired by Aduro Biotech in 2015 for its proprietary B-select antibody technology platform and pipeline.
To view Dr. Olijve’s bio, please visit the Aduro website at: http://www.aduro.com/about/scientific-advisory-board.
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of LADD, or pLADD, is in Phase 1 development utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro’s STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our technology platforms, plans, and the potential for eventual regulatory approval of our product candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2017, which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
SVP, Corporate Affairs
510 809 9264
510 809 2452